Hanmeng Xu, Camila Aparicio-Llorente, Aanchal Wats, Barbara L Araujo, Julia Moniz Ganem, Isabela O Oliva, Eugene D Shapiro, Nina N Brodsky, Paul L Aronson, Nathan D Grubaugh, Carrie L Lucas, Linda M Niccolai, Joshua L Warren, Lee Kennedy-Shaffer, Virginia E Pitzer, Daniel M Weinberger, Carlos R Oliveira
In this test-negative study, the effectiveness of the maternal RSVpreF vaccine among infants <6 months was 73.9% against medically attended respiratory syncytial virus (RSV) infection and 86.3% against RSV-associated hospitalization. Maternal RSVpreF and nirsevimab had comparable initial effectiveness, but effectiveness of RSVpreF waned approximately 1.7 times more rapidly.